EQL Pharma inleder 2026/27 med en oförändrad omsättning på 107 MSEK och en försvagad lönsamhet.
BeammWave surprised by stating it is advancing a global tier-1 Asian technology partner from an init...
LAIQON turned EBITDA positive in Q2 for the first time in years and Digital Wealth is scaling fast e...
* Sales SEK 1,558m & EBIT 68m * Earnings beat across all segments * Share currently trading at 15-10...
Taaleri’s Q2 2026 continuing earnings of EUR 9.8m declined by 8% y/y and came 7% below our estimate.
JonDeTech redovisade fortsatt begränsade intäkter men minskad rörelseförlust och stärkt finansiering...
Redeye provides an update following Neem's Hill's Q2 2026 report.
Redeye updates on Better Collective ahead of Q2-results (due 20 August after market close) where we ...
* Q2 paper EBIT of PLN -32m * Pulp prices down, while paper remains challenging * Fair value range o...
We forecast an improving H2 performance for Siili. Although the company’s headline Q2 performance do...
Inderes’ H1 demonstrated the underlying strength of the Finnish market, with solid growth as market ...
Redeye gives an initial comment on the new data published earlier today.
Endomines published its first tungsten and molybdenum drilling results from 2023-2026.
* We expect growth to return in a seasonally soft quarter * Estimates unchanged but costs elevated n...
Stark tillväxt och tydligt marginallyft Gullberg & Jansson redovisade ett starkt andra kvartal där ...
Redeye provides a preview ahead of Smart Eye's Q2 2026 earnings report, scheduled for release on Aug...
Redeye provides an initial take following Neem’s Hill’s Q2 2026 report.
Siili continued to struggle with sales growth in Q2, which saw sales decline by 12% y/y, missing our...
Yesterday, QBY reported a weak Q2 and cut its FY26 guidance significantly, with both events telling ...
Redeye comments on EG7 ahead of Q2-results (due 19 August) where we expect a strong report driven by...